Keith Flaherty

Keith Flaherty is Director of Clinical Research at the Massachusetts General Hospital Cancer Center and Professor of Medicine at Harvard Medical School.[1] He was previously a professor of medicine at the University of Pennsylvania. He is known for his research on targeted therapies for cancer, and in particular for his work on the melanoma drug vemurafenib.[2][3][4][5] In 2013, Massachusetts General Hospital partnered with AstraZeneca to partner Flaherty's research into developing a formula to identify vulnerabilities of tumors with AstraZeneca's library of drugs.[6]

References

  1. ^ Keith T. Flaherty, MD - Massachusetts General Hospital, Boston, MA
  2. ^ Target Cancer - A Roller Coaster Chase for a Cure - Series - NYTimes.com
  3. ^ Target Cancer - After Long Fight, Melanoma Drug Gives Sudden Reprieve - Series - NYTimes.com
  4. ^ Target Cancer - A Drug Trial Cycle - Recovery, Relapse, Reinvention - Series - NYTimes.com
  5. ^ Inhibition of Mutated, Activated BRAF in Metastatic Melanoma — NEJM
  6. ^ Weintraub, Karen (19 May 2013). "MGH, AstraZeneca partner to create new drug combos". Boston Globe. Archived from the original on 8 April 2015. Retrieved 30 January 2015.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.